Biocon Biologics reaches settlement with Amgen for Denosumab biosimilars commercialisation
Agreement enables Europe launch of Vevzuo and Evfraxy from December 2025
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Biocon Biologics
Health Canada grants NOC for Biocon Biologics’ Yesintek and Yesintek I.V
Biocon Biologics receives Canadian approval for ustekinumab biosimilars for autoimmune conditions
Biocon Biologics expands partnership with Civica to launch Insulin Glargine in the US
Biocon Biologics and Civica collaboration aims to increase access to affordable insulin in the United States
Panel Discussion: Bengaluru: An emerging global innovation gateway?
Bengaluru, known globally as India’s IT capital, is now fast emerging as a powerful hub for pharma and life sciences. With its…
Biocon Biologics clears path for U.S. launch of denosumab biosimilars Bosaya and Aukelso
Settlement with Amgen enables commercialisation of Bosaya and Aukelso in the United States from October 1, 2025
Biocon Biologics appoints Deepali Naair as head, corporate communications
Seema Ahuja will post her retirement from Biocon Biologics move into a non-business facing role in Biocon Chairperson’s office
Biocon Biologics gains USFDA approval for Kirsty, Interchangeable Rapid-Acting Insulin Aspart
KIRSTY will be available as a single-patient-use prefilled pen for subcutaneous use and a multiple-dose vial for subcutaneous and…
Biocon Biologics gains UK approval for Vevzuo and Evfraxy, Denosumab Biosimilars
Vevzuo is authorised for the prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord…
EU approves Biocon Biologics’ Denosumab biosimilars
Denosumab is a human monoclonal antibody that targets and binds a protein known as RANKL (Receptor Activator of Nuclear Factor…
Biocon Biologics, Yoshindo launch Ustekinumab biosimilar in Japan
Ustekinumab, a monoclonal antibody, is approved for the treatment of psoriasis vulgaris and psoriatic arthritis (PsA)